Leaflet: information for the user
TOPAMAX DISPERSABLE 15 mg hard capsules
topiramate
This medicine is subject to additional monitoring, which will speed up the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section 4 includes information on how to report these adverse effects.
Read this leaflet carefully before starting to take this medicine, because it contains important information for you.
6. Contents of the pack and additional information
Topamax dispersablebelongs to a group of medicines called “antiepileptic medicines”. It is used for:
Do not take Topamax dispersable
Prevention of migraines
Treatment of epilepsy
Make sure to read the patient guide that you will receive from your doctor or scan the QR code to obtain it (see section 6 “Other sources of information”).
A patient card is provided with the packaging of Topamax dispersable to remind you of the risks during pregnancy.
If you are unsure whether any of the above applies to you, consult your doctor or pharmacist before using Topamax dispersable.
Warnings and precautions
Consult your doctor before starting to take Topamax dispersable if you:
If you have epilepsy, it is essential not to stop taking your medication without consulting your doctor first.
You should consult your doctor before taking any other medication containing topiramate that is given as an alternative to Topamax dispersable.
You may lose weight if you take Topamax dispersable, so your weight should be monitored regularly while taking this medication. If you lose too much weight or if a child taking this medication does not gain enough weight, you should consult your doctor.
A small number of people being treated with antiepileptic medications like Topamax dispersable have had thoughts of self-harm or suicide. If you ever have these thoughts, contact your doctor immediately.
Topamax dispersable may cause severe skin reactions. Contact your doctor immediately if you develop a skin rash and/or blisters (see also section 4 “Possible side effects”).
Topamax dispersable may cause high levels of ammonia in the blood (seen in blood tests) which can cause a change in brain function, especially if you are also taking a medication called valproic acid or valproate sodium. Since this can be a serious condition, talk to your doctor immediately if you experience any of the following symptoms (see also section 4 “Possible side effects”):
You may be at increased risk of developing these symptoms at higher doses of Topamax dispersable.
Other medications and Topamax dispersable
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication. Topamax dispersable and certain medications may affect each other. Sometimes, the dose of one or both medications may need to be adjusted.
Especially, inform your doctor or pharmacist if you are taking:
Tell your doctor if you change your menstrual bleeding while taking hormonal contraceptives and Topamax dispersable. You may experience irregular bleeding. In this case, continue taking the hormonal contraceptives and inform your doctor.
Keep a list of all the medications you take. Show this list to your doctor and pharmacist before starting a new medication.
Other medications that you should consult your doctor or pharmacist about include other antiepileptic medications, risperidone, lithium, hydrochlorothiazide, metformin, pioglitazone, glibenclamide, amitriptyline, propranolol, diltiazem, venlafaxine, flunarizine, St. John's Wort (Hypericum perforatum) (a herbal preparation used to treat depression), and warfarin used to prevent blood clotting.
If you are unsure whether any of the above applies to you, consult your doctor or pharmacist before taking Topamax dispersable.
You can take Topamax dispersable with or without food. Drink plenty of liquid during the day to prevent kidney stone formation while taking Topamax dispersable. You should avoid drinking alcohol while taking Topamax dispersable.
Important advice for fertile women:
Topamax dispersable may cause harm to a baby during gestation. If you are a fertile woman, consult your doctor about other possible treatments. Visit your doctor to review your treatment and discuss the risks at least once a year.
Prevention of migraines
Treatment of epilepsy
Risks of topiramate when taken during pregnancy (regardless of the condition for which topiramate is used) are as follows:
There is a risk of harm to a baby during gestation if Topamax dispersable is used during pregnancy.
Birth defects.
Necessity of contraceptive methods for fertile women:
If you are the parent/caregiver of a girl being treated with Topamax dispersable, you should consult your doctor immediately once your daughter experiences her first menstrual period (menarche). The doctor will inform you about the risks to a baby during gestation due to exposure to topiramate during pregnancy and about the need to use highly effective contraceptive methods.
If you want to become pregnant while taking Topamax dispersable:
If you have become pregnant or think you may be pregnant while taking Topamax dispersable:
Breastfeeding
The active ingredient of Topamax dispersable (topiramate) passes into breast milk. Adverse effects have been observed in breastfed infants of mothers treated with Topamax dispersable, including diarrhea, drowsiness, irritability, and low weight gain. Therefore, your doctor will discuss with you whether to interrupt breastfeeding or whether to interrupt the treatment with Topamax dispersable. Your doctor will take into account the importance of the benefits for the mother and the risk to the baby.
Mothers who are breastfeeding and taking Topamax dispersable should inform their doctor as soon as possible if the baby experiences anything unusual.
Driving and operating machines
You may experience dizziness, fatigue, and visual disturbances during treatment with Topamax dispersable. Do not drive or operate tools or machines without talking to your doctor first.
Topamax dispersable contains saccharose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Topamax dispersable treatment should begin and continue under the supervision of a doctor experienced in treating epilepsy or migraine. Visit your doctor to review your treatment at least once a year.
If you take more Topamax dispersable than you should
You may experience an overdose if you are taking another medication with Topamax dispersable.
In case of overdose or accidental ingestion, you can also consult the Toxicological Information Service, Phone 91 5620420.
If you forgot to take Topamax dispersable
If you interrupt the treatment with Topamax dispersable
Do not stop treatment without your doctor telling you to do so. Your symptoms may return. If your doctor decides you should stop taking this medication, they will gradually reduce your dose over several days.
If you have any other doubts about using this product, ask your doctor or pharmacist.
Consult your doctor or seek immediate medical attention if you experience the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not known (cannot be estimated from available data):
Other side effects include the following, if severe, please consult your doctor or pharmacist:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
No conocida (no puede estimarse a partir de los datos disponibles)
Other side effects in children
Generally, side effects observed in children are similar to those observed in adults, but the following side effects may be more common in children than in adults:
Other side effects that may occur in children are:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Communication of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through theSistema Español de Farmacovigilancia de Medicamentos de Uso Humano:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears on the bottle/carton after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C. Keep the bottle perfectly closed to protect the capsules from moisture.
Medicines should not be disposed of through drains or in the trash.Deposit the containers and medicines that you no longer need at theSIGREpharmacy drop-off point. If in doubtask your pharmacist how to dispose of the containers and medicines that you no longer need. By doing so, you will help protect the environment.
Composition of Topamax Dispersable
15 mg capsules: Small white to off-white spheres in a hard gelatin capsule with a white opaque body with a legend engraved “15” and a transparent cap with a legend engraved “TOP”.
HDPE opaque plastic bottle with a child-resistant closure containing 20, 28, 60 or 100 capsules with granules.
Only some package sizes may be marketed.
Marketing authorization holder
JANSSEN-PHARMA, S.L.
Pº de las Doce Estrellas, 5-7
28042 Madrid
Spain
Responsible manufacturer
Janssen-Cilag S.p.a
04100 Borgo S. Michele
Latina
Italy
Austria, Belgium, Cyprus, Czech Republic, Germany, Italy, Luxembourg, Malta, Poland, Portugal, Slovenia: | Topamax |
Denmark, Finland, Iceland, Norway, Sweden: | Topimax |
France: | Epitomax |
Greece: | Topamac |
Ireland, Netherlands: | Topamax Sprinkle |
Spain: | Topamax Dispersable |
Last review date of this leaflet:March 2024.
The most recent approved patient guide information for this medicinal product is available by scanning the following QR code with a smartphone. The same information is also available on the following website (URL):
https://cima.aemps.es/cima/DocsPub/16/3252
Detailed information about this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.